Pediatric Nephrology

, Volume 17, Issue 9, pp 748–753

Isradipine treatment of hypertension in children: a single-center experience

  • Joseph T. Flynn
  • Stephen J. Warnick
Hypertension

DOI: 10.1007/s00467-002-0939-6

Cite this article as:
Flynn, J.T. & Warnick, S.J. Pediatr Nephrol (2002) 17: 748. doi:10.1007/s00467-002-0939-6

Abstract.

Many children with hypertension, particularly those with new-onset hypertension related to glomerulonephritis, organ transplantation, or other forms of secondary hypertension, require treatment with a short-acting antihypertensive in order to quickly achieve blood pressure (BP) control. We administered isradipine, a short-acting, second-generation calcium antagonist, to 72 such children. Retrospective data collection was undertaken to determine the effects of isradipine treatment. The mean age of children treated with isradipine was 74±55 months (mean±SD). Nearly all of these children had secondary hypertension and were initially treated as hospital inpatients for newly diagnosed hypertension. Mean isradipine dose was 0.36±0.17 mg/kg per day, with no significant variation in dose according to patient age. Isradipine was administered three times per day in most instances, but 21% of the time it was administered four times per day. An extemporaneous isradipine suspension was used in 62% of treatment courses. BP control was achieved with isradipine alone in 38 children; the remainder received isradipine in combination with additional antihypertensives. Comparison of pre-treatment BP with BP obtained 8±9 days later demonstrated a significant BP reduction with isradipine treatment, with a mean reduction of 14±13 mmHg for systolic BP and 13±15 mmHg for diastolic BP. There was no effect of isradipine treatment on heart rate. Adverse effects occurred in 9.5% of treatment courses, and included headache, flushing, dizziness, and tachycardia. We conclude that isradipine successfully lowers BP in hypertensive children with secondary forms of hypertension. Use of isradipine suspension allows infants and young children to be treated as readily as older children.

Clinical trial Calcium channel blocker Dihydropyridine Secondary hypertension Nifedipine Amlodipine 

Copyright information

© IPNA 2002

Authors and Affiliations

  • Joseph T. Flynn
    • 1
  • Stephen J. Warnick
    • 2
  1. 1.Department of Pediatrics, Division of Pediatric Nephrology, Albert Einstein College of Medicine, Bronx, New York, USA
  2. 2.Undergraduate Research Opportunity Program, College of Literature, Science and the Arts, University of Michigan, Ann Arbor, Michigan, USA
  3. 3.Division of Pediatric Nephrology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA

Personalised recommendations